Canopy Growth Corporation (CGC)
NASDAQ: CGC · Real-Time Price · USD
1.150
-0.050 (-4.17%)
At close: Apr 28, 2026, 4:00 PM EDT
1.150
0.00 (0.00%)
Pre-market: Apr 29, 2026, 7:56 AM EDT
Canopy Growth Revenue
Canopy Growth had revenue of 74.54M CAD in the quarter ending December 31, 2025, a decrease of -0.29%. This brings the company's revenue in the last twelve months to 278.39M, up 0.59% year-over-year. In the fiscal year ending March 31, 2025, Canopy Growth had annual revenue of 269.00M, down -9.47%.
Revenue (ttm)
278.39M CAD
Revenue Growth
+0.59%
P/S Ratio
2.17
Revenue / Employee
289,989 CAD
Employees
960
Market Cap
439.92M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 269.00M | -28.15M | -9.47% |
| Mar 31, 2024 | 297.15M | -36.11M | -10.83% |
| Mar 31, 2023 | 333.25M | -142.45M | -29.94% |
| Mar 31, 2022 | 475.70M | -70.95M | -12.98% |
| Mar 31, 2021 | 546.65M | 147.88M | 37.08% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 742.90M |
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 403.14M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Akebia Therapeutics | 236.20M |
| Kamada | 180.46M |
| SIGA Technologies | 94.57M |
CGC News
- 1 day ago - Canopy Growth Stock Is Jumping. Is It Overdue for a Much Bigger Rally? - The Motley Fool
- 4 days ago - Canopy Growth Is Rallying Again. But Is It a Dead Cat Bounce? - The Motley Fool
- 4 days ago - Akanda Shares Soar As Cannabis Stocks Rise On US Policy Change - Benzinga
- 5 days ago - 'Big Business Opportunity': Cannabis CEO Celebrates DOJ Easing Regulations On Medical Marijuana - Forbes
- 5 days ago - The cannabis rescheduling is causing celebration — and confusion — as marijuana stocks sell off - Market Watch
- 5 days ago - Cannabis Stocks Soared—Than Sank. Here's What Investors Need to Know. - Investopedia
- 5 days ago - Cannabis rescheduling fuels optimism across industry - Reuters
- 5 days ago - What's Going On With Canopy Growth Stock Thursday? - Benzinga